Search Videos and More
News
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study
News
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024
Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
Video
Bladder Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2024.
Video
Kidney Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2024.
Video
Prostate Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2024.
News
Immunotherapy for Cancer: What it Is, How it Works, and Where it’s Going
Immunotherapy refers to treatments that use the body’s immune system to combat diseases. Immuno-oncology focuses on efforts to use the immune system as a weapon against cancer. The immune system is a collection of organs, tissues, specialized cells, and substances that protect the body against infection and disease. While the immune system can often handle very small tumors on its own, either by destroying them or keeping them from growing, it can sometimes fail — either because a tumor grows too large, the cancer cells are too well camouflaged, or the tumor cells are able to stave off an immune system attack. A key discovery, made by Dana-Farber’s Gordon Freeman, PhD, and others, was that the immune system’s attack on cancer often falls short because many cancer cells display proteins, called immune checkpoint proteins, that bring the attack to a halt.
News
Immunotherapy Post-Surgery Improves Overall Survival For Kidney Cancer
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo.
News
Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides
A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma (ccRCC), a form of kidney cancer, using image processing with deep learning.
News
Study Shows Immunotherapy May Benefit a Subset of Patients with Penile Cancer
Penile cancer is a rare disease with approximately 2070 new cases each year in the US.
Video
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
News
Treatment Decisions in New Era of Individualized Therapy For Metastatic Hormone-Sensitive Prostate Cancer Guided by Dana-Farber Case Study
Oncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
News
Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study